Metformin versus Insulin for the Treatment of Gestational Diabetes
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Metformin is a logical treatment for women with gestational diabetes mellitus, but randomized trials to assess the efficacy and safety of its use for this condition are lacking. METHODS: We randomly assigned 751 women with gestational diabetes mellitus at 20 to 33 weeks of gestation to open treatment with metformin (with supplemental insulin if required) or insulin. The primary outcome was a composite of neonatal hypoglycemia, respiratory distress, need for phototherapy, birth trauma, 5-minute Apgar score less than 7, or prematurity. The trial was designed to rule out a 33% increase (from 30% to 40%) in this composite outcome in infants of women treated with metformin as compared with those treated with insulin. Secondary outcomes included neonatal anthropometric measurements, maternal glycemic control, maternal hypertensive complications, postpartum glucose tolerance, and acceptability of treatment. RESULTS: Of the 363 women assigned to metformin, 92.6% continued to receive metformin until delivery and 46.3% received supplemental insulin. The rate of the primary composite outcome was 32.0% in the group assigned to metformin and 32.2% in the insulin group (relative risk, 0.99 [corrected]; 95% confidence interval, 0.80 [corrected] to 1.23 [corrected]). More women in the metformin group than in the insulin group stated that they would choose to receive their assigned treatment again (76.6% vs. 27.2%, P<0.001). The rates of other secondary outcomes did not differ significantly between the groups. There were no serious adverse events associated with the use of metformin. CONCLUSIONS: In women with gestational diabetes mellitus, metformin (alone or with supplemental insulin) is not associated with increased perinatal complications as compared with insulin. The women preferred metformin to insulin treatment. (Australian New Zealand Clinical Trials Registry number, 12605000311651.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While individual RCTs support limited efficacy of metformin (73,74) and glyburide (75) in reducing glucose levels for the treatment of GDM, these agents are not recommended as the first-line treatment for GDM because they are known to cross the placenta and data on long-term safety for offspring is of some concern (35).”
From 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024 (2024) · cites this paper as [73]
In the citing paper
“It was concluded that metformin alone, or with supplemental insulin, was not associated with increased perinatal complications.”
From Gestational Diabetes Mellitus—Recent Literature Review (2022) · cites this paper as [112]
In the citing paper
“Blood glucose-lowering pharmacological therapy is effective at improving outcomes in women with gestational diabetes whose hyperglycemia does not respond sufficiently to lifestyle therapy (71, 82, 88–90).”
From Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline (2013) · cites this paper as [90]
In the citing paper
“Blood glucose-lowering pharmacological therapy is effective at improving outcomes in women with gestational diabetes whose hyperglycemia does not respond sufficiently to lifestyle therapy (71, 82, 88–90).”
From Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline (2013) · cites this paper as [89]
In the citing paper
“Glyburide is effective in controlling blood glucose in women with gestational diabetes”
From Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline (2013) · cites this paper as [90]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Effect of Treatment of Gestational Diabetes Mellitus on Pregnancy Outcomes
Crowther, C. A., Hiller, J. E., Moss, J. R., McPhee, A. J., Jeffries, W. S., & Robinson, J. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042973 · Cited by 3,159
Dabelea, D., Hanson, R. L., Lindsay, R. S., Pettitt, D. J., Imperatore, G., Gabir, M. M., Roumain, J., Bennett, P. H., & Knowler, W. C. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2208 · Cited by 1,277
Kirpichnikov, D., McFarlane, S. I., & Sowers, J. R. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00009 · Cited by 1,084
A comparison of glyburide and insulin in women with gestational diabetes mellitus
Langer, O., Conway, D. L., Berkus, M. D., Xenakis, E. M.-J., & Gonzales, O. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431601 · Cited by 924
Epidemiology of gestational diabetes mellitus and its association with Type 2 diabetes
Ben‐Haroush, A., Yogev, Y., & Hod, M. (2004) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.00985.x · Cited by 856
Gestational diabetes: The consequences of not treating
Langer, O., Yogev, Y., Most, O., & Xenakis, E. M. J. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.11.039 · Cited by 677
Silverman, B. L., Metzger, B. E., Cho, N. H., & Loeb, C. A. (1995) · Diabetes Care · doi:10.2337/diacare.18.5.611 · Cited by 643
Hoffman, L., Nolan, C., Wilson, J. D., Oats, J. J. N., & Simmons, D. (1998) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1998.tb140192.x · Cited by 570
An Increase in the Incidence of Gestational Diabetes Mellitus: Northern California, 1991–2000
Ferrara, A., Kahn, H. S., Quesenberry, C. P., Riley, C., & Hedderson, M. M. (2004) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000113623.18286.20 · Cited by 452
Glueck, C. J., Phillips, H., Cameron, D., Sieve-Smith, L., & Wang, P. (2001) · Fertility and Sterility · doi:10.1016/s0015-0282(00)01666-6 · Cited by 430
Research works printed but not linked: 3
- Coetzee EJ, 1980, S Afr Med J, 58, 795
- Coetzee EJ, 1984, S Afr Med J, 65, 635
- Gutzin SJ, 2003, Can J Clin Pharmacol, 10, 179
Cited by
Items 601–700 of 1,001
Metformin and its redox-related mechanisms of action in type 2 diabetes
Vezza, T., Luna-Marco, C., Rovira‐Llopis, S., & Víctor, V. M. (2023) · Redox Experimental Medicine · doi:10.1530/rem-23-0015 · Cited by 8
Venkatesh, K. K., Wu, J., Trinh, A., Cross, S., Rice, D., Powe, C. E., Brindle, S., Andreatta, S., Bartholomew, A. B. C., MacPherson, C., et al. (2023) · American Journal of Perinatology · doi:10.1055/s-0043-1777334 · Cited by 9
Preditores de sucesso da metformina no tratamento do diabetes mellitus gestacional
Silva, J. C., de Souza, B. V., & Silva, M. R. E. (2013) · Revista Brasileira de Saúde Materno Infantil · doi:10.1590/s1519-38292013000200006 · Cited by 13
Metformin Opposed to Insulin in the Management of Gestational Diabetes
Borg, H. M., & Ezat, S. (2016) · Cited by 9
Moll, U., Landin‐Olsson, M., Nilsson, C., Ursing, D., & Strevens, H. (2019) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.13758 · Cited by 8
Insulin Therapy and Diabetic Pregnancy
Napoli, A. (2019) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001095 · Cited by 9
Metformin administration during pregnancy — current insight
Skibińska, M., Żurawska-Kliś, M., Krekora, M., & Cypryk, K. (2021) · Ginekologia Polska · doi:10.5603/gp.a2020.0149 · Cited by 8
Li, F., Liu, L., Hu, Y., Marx, C. M., & Liu, W. (2022) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-022-01438-z · Cited by 11
“Thus, patients may prefer metformin instead of insulin [33].”
BackgroundMaternal Obesity and Pregnancy
Dennedy, M. C., & Dunne, F. (2012) · Springer eBooks · doi:10.1007/978-3-642-25023-1_7 · Cited by 11
Diabetes and Endocrine Disease in Pregnancy
Dornhorst, A., & Williamson, C. (2012) · Wiley-Blackwell eBooks · doi:10.1002/9781119979449.ch13 · Cited by 9
A review of insulin and insulin regimens in type 2 diabetes
Joshi, S., & Joshi, P. (2009) · South African Family Practice · doi:10.1080/20786204.2009.10873820 · Cited by 8
Metformin in gestational diabetes mellitus
Tripathi, R., Tyagi, S., & Goel, V. (2017) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_1572_16 · Cited by 8
GESTATIONAL DIABETES MELLITUS;
Hashmi, K. S., Akhtar, T., Batool, S., & Saleem, K. (2019) · The Professional Medical Journal · doi:10.29309/tpmj/2019.26.01.2593 · Cited by 8
Metformin in overweight and obese women with gestational diabetes: a propensity score-matched study
Bettencourt‐Silva, R., Neves, J. S., Ferreira, M. J., Souteiro, P., Belo, S., Oliveira, A. I., Carvalho, D. M., Namora, G., Montenegro, N. A. M. D. M., & Queirós, J. C. (2019) · Endocrine · doi:10.1007/s12020-019-02043-3 · Cited by 9
Diseases of the Reproductive System
Troedsson, M. H. T., Christensen, B. W., Varner, D. D., Brinsko, S. P., Woodward, E. M., McNabb, B. R., & Romano, J. E. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-55445-9.00043-4 · Cited by 8
Decesare, J. Z. (2017) · Cambridge University Press eBooks · doi:10.1017/9781316662571.029 · Cited by 8
Medical Issues from Preconception Through Delivery: A Roadmap for the Internist
Carson, M., & Ehrenthal, D. B. (2008) · Medical Clinics of North America · doi:10.1016/j.mcna.2008.04.010 · Cited by 9
Le diabète gestationnel : diagnostic et prise en charge à court et à long terme
Vambergue, A. (2013) · La Presse Médicale · doi:10.1016/j.lpm.2013.02.316 · Cited by 8
Glyburide for Gestational Diabetes: Time for a Pause for Thought
Holt, R. I. G. (2015) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2015.144 · Cited by 8
Metformin for Diabetes in Pregnancy: Are We Closer to Defining Its Role?
Feig, D. S. (2023) · JAMA · doi:10.1001/jama.2023.18589 · Cited by 8
Venkatesh, K. K., MacPherson, C., Clifton, R. G., Powe, C. E., Bartholomew, A. B. C., Gregory, D., Trinh, A., McAlearney, A. S., Fiechtner, L. G., Catalano, P. M., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-091176 · Cited by 9
“20 Based on the above assumptions, we plan to enrol 1572 individuals to determine if metformin is non-inferior to insulin for the composite primary outcome, with 90% power, one-sided significance level of 0.025, a loss to follow-up at delivery of 2% and 20% supplementation with insulin in addition…”
InfluentialMatallana, C. D. P., Blanco‐Carnero, J. E., Fernandez, M., Lewanczyk, M., Burton, M., Yang, X., Mitchell, A., Lövgren‐Sandblom, A., Marschall, H., Wright, D. E., et al. (2025) · American Journal of Obstetrics & Gynecology MFM · doi:10.1016/j.ajogmf.2025.101732 · Cited by 7
Wu, R., & Li, Z. (2024) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-024-07483-5 · Cited by 8
“A significant randomized controlled trial proved that for patients with GDM, metformin (alone or with supplemental insulin) is as safe and effective as insulin alone [9].”
Rawat, D., Gupta, Y., Yadav, A. K., Tembhre, M. K., Das, P., Bakkireddy, S., Singh, N., Sharma, K. A., Zangmo, R., Chandra, A., et al. (2024) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2024.103134 · Cited by 8
Is metformin safe in pregnancy: a focus on offspring outcomes
Malek, R., & Davis, S. N. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2424410 · Cited by 11
The Role of Metformin in Treating Preeclampsia
Cheng, D., Zhou, X., & Xu, X. (2021) · Maternal-Fetal Medicine · doi:10.1097/fm9.0000000000000086 · Cited by 8
“However, at least this drug is clearly safe during pregnancy and is accepted well by pregnant women when compared with insulin alone.(30)”
BackgroundMethodRisk of metformin failure in the treatment of women with gestational diabetes
Herrera, K. M., Ou, J. P., Persad, M. D., Bernasko, J., Garretto, D. J., & Garry, D. J. (2021) · Journal of Perinatal Medicine · doi:10.1515/jpm-2020-0435 · Cited by 7
Metformin in Pregnancy for Women with Type 2 Diabetes: a Review
Benham, J. L., Donovan, L., & Yamamoto, J. M. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01409-0 · Cited by 8
“Notably, gestational age at birth and preterm birth were not different between treatment arms of this trial, unlike the women with gestational diabetes randomized to metformin in the MiG trial [18].”
ResultBoroumand, F., Ghayur, S., Gharaaghaji, R., & Vazifekhah, S. (2022) · Journal of Obstetrics Gynecology and Cancer Research · doi:10.30699/jogcr.7.6.524 · Cited by 7
“study showed no difference in birth weight for women with gestational diabetes receiving metformin/insulin (16).”
BackgroundGestational Diabetes in the Gulf Region: Streamlining care to optimise outcome
Okunoye, G. O., Konje, J. C., Lindow, S. W., & Perva, S. (2015) · Journal of Local and Global Health Science · doi:10.5339/jlghs.2015.2 · Cited by 7
Comparison of metformin and insulin in the treatment of gestational diabetes: a retrospective study
Bansal, N., Chaudhary, P., Ramola, M., & Saxena, N. (2016) · International Journal of Reproduction Contraception Obstetrics and Gynecology · doi:10.18203/2320-1770.ijrcog20164342 · Cited by 7
“Caesarean section, n (%) 15 (30) 10 (20) 10 (20) NS”
Implications of maternal obesity on fetal growth and the role of ultrasound
O’Brien, C. M., Poprzeczny, A. J., & Dodd, J. M. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2017.1271707 · Cited by 7
“Ongoing follow-up of the children whose mothers participated in these trials is important, as there is evidence that the use of metformin in the treatment of gestational diabetes is associated with lower visceral body fat at 2 years of age compared with children born to women who had treatment with insulin [125], desp…”
BackgroundMalfertheiner, S. F., Gutknecht, D., & Bals‐Pratsch, M. (2017) · Geburtshilfe und Frauenheilkunde · doi:10.1055/s-0043-122279 · Cited by 8
“…differences with regard to neonatal weight, gestational age, state of health, perinatal mortality and rate of preterm delivery between insulin and metformin used to treat GDM; however, rates of neonatal hypoglycemia in newborns were reduced in the GDM group treated with metformin [12,15,16].”
Pancer, J., Wu, N., Mahmoud, I., & Dasgupta, K. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.107998 · Cited by 7
do Nascimento, I. B., Fleig, R., de Souza, M. L. R., & Silva, J. C. (2020) · Revista Brasileira de Saúde Materno Infantil · doi:10.1590/1806-93042020000100002 · Cited by 33
Pagotto, V., Posadas Martínez, M. L., Salzberg, S., & Pochettino, P. A. (2022) · Revista de la Facultad de Ciencias Médicas de Córdoba · doi:10.31053/1853.0605.v79.n3.36734 · Cited by 7
Rowan, J., Rush, E. C., & Plank, L. D. (2023) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/ajo.13739 · Cited by 7
Self-citationMonitoring and managing mothers with gestational diabetes mellitus: a nursing perspective
Berry, D. C., Johnson, Q. B., & Stuebe, A. (2015) · Nursing Research and Reviews · doi:10.2147/nrr.s64534 · Cited by 10
“Although women randomized to metformin seemed to prefer this mode of medication delivery, unfortunately, approximately 50% still required insulin to meet their glycemic goals.(37) Further well-designed randomized controlled trials are needed to fully examine the risk to the fetus.”
Metformin and other biguanides: pharmacology and therapeutic usage
Samson, S. L., & Garber, A. J. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch43 · Cited by 9
McCance, D. R., & Cassidy, L. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch71 · Cited by 9
Liu, J., Shen, L., Nguyen‐Hoang, L., Zhou, Q., Wang, C. C., Lu, X., Sahota, D. S., Chong, K. C., Ying, H., Gu, W., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-074493 · Cited by 7
“22– 24 Metformin can cross the placenta freely, while being poorly metabo-lised by the fetus, as many studies have shown no evidence of a higher chance of premature labour, macrosomia and morbidity or mortality of the child up to first year of life.”
BackgroundBrinkmann, M. L. S., Krasilnikoff, N. J., Chaaban, M. A., Luef, B. M., Newman, C., Dunne, F., Jensen, D. M., & Vinter, C. A. (2025) · Diabetic Medicine · doi:10.1111/dme.70173 · Cited by 7
Wilkie, G., Delpapa, E. H., & Leftwich, H. K. (2021) · American Journal of Perinatology · doi:10.1055/a-1682-2643 · Cited by 8
Stolzenbach, F., Gloria, A.-F., Pérez-Bustamante, M., Camila, N.-C., Víctor, C., & Kerr, B. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167258 · Cited by 8
Yang, Z., Shi, X., Wang, S., Du, L., Zhang, X., Zhang, K., Zhang, Y., Ma, J., & Zheng, R. (2025) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.70055 · Cited by 10
Movva, B. (2014) · Journal of Bioequivalence & Bioavailability · doi:10.4172/jbb.10000187 · Cited by 6
Poprzeczny, A. J., Louise, J., Deussen, A. R., & Dodd, J. M. (2020) · BMC Endocrine Disorders · doi:10.1186/s12902-020-00618-0 · Cited by 6
An Overview of Gestational Diabetes
Federico, C., & Pridjian, G. C. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-385083-6.00016-4 · Cited by 6
Challenges Facing during Pregnancy and Measures to Overcome
Ramalingam, G. D., Sampath, S. K., & Amirtham, J. P. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.100614 · Cited by 8
Controversies in Gestational Diabetes
Zera, C., & Seely, E. W. (2021) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2021.17.2.102 · Cited by 10
“In the Metformin in GDM (MiG) trial, a multicenter study performed in New Zealand and Australia, 751 women with GDM diagnosed by 75 g OGTT who needed pharmacologic treatment between 20 and 33 weeks + 6 days gestation were randomized to insulin or metformin starting at 500 mg, titrated to a maximal dose of 2,500 mg dai…”
BackgroundMethodSuboptimally Controlled Diabetes in Pregnancy: A Review to Guide Antepartum and Delivery Management
Cate, J. J. M., Bloom, E. A., Chu, A., Bauer, S., Kuller, J. A., & Dotters-Katz, S. K. (2024) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000001270 · Cited by 7
“53,54 In a meta-analysis by Farrar et al comparing insulin, metformin, and glyburide, metformin was associated with lowest risk of common adverse neonatal outcomes such as hypoglycemia, macrosomia, LGA, and preterm birth risk, as well as maternal preeclampsia.”
BackgroundIs metformin ready for prime time in pregnancy? Probably not yet
Fantus, I. G. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2587 · Cited by 7
Gestational diabetes: what’s new?
Murphy, H. R. (2010) · Medicine · doi:10.1016/j.mpmed.2010.08.014 · Cited by 7
Enrique Valdés, R., Soto-Chacón, E., Lahsen, R., Carlos Barrera, H., & Paula Candia, P. (2008) · Revista médica de Chile · doi:10.4067/s0034-98872008000700015 · Cited by 9
Preconception Care for Women With Preexisting Type 2 Diabetes
Roman, M. A. (2011) · Clinical Diabetes · doi:10.2337/diaclin.29.1.10 · Cited by 7
Review of metformin and glyburide in the management of gestational diabetes
Carroll, D. G., & Kelley, K. W. (2014) · Pharmacy Practice · doi:10.4321/s1886-36552014000400001 · Cited by 8
“In 2008, the MiG trial was published.(20) It was a large (n=751) randomized, open label trial comparing metformin to insulin.”
BackgroundMontaner, P., Ripollés, J., Pamies, C., & Corcoy, R. (2011) · Journal of obstetrics and gynaecology research · doi:10.1111/j.1447-0756.2010.01415.x · Cited by 7
Gestational Diabetes Testing: Making Sense of the Controversy
Salmeen, K. E. (2016) · Journal of Midwifery & Women s Health · doi:10.1111/jmwh.12377 · Cited by 7
The diversity of gestational diabetes: a therapeutic challenge
Qvigstad, E. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0012 · Cited by 7
Gestational Diabetes Mellitus: Challenges in Diagnosis and Management
Roy, P., Agrawal, P. K., Garg, R., Gautam, A., Hokabaj, S., & Goel, H. (2018) · Journal of South Asian Federation of Obstetrics and Gynaecology · doi:10.5005/jp-journals-10006-1558 · Cited by 7
Diabetes in pregnancy: a practical guide for midwives
Aarthi, S., Dixon, D. J., & Whyte, M. (2019) · British Journal of Midwifery · doi:10.12968/bjom.2019.27.7.413 · Cited by 7
Gestational Diabetes Mellitus: Diagnosis and Glycemic Control
Oh, T. J., & Jang, H. C. (2020) · Journal of Korean Diabetes · doi:10.4093/jkd.2020.21.2.69 · Cited by 6
“고혈압 발생 예방 및 거대아 출산 위험도를 낮추는 데 유리 한 결과를 가지고 있지만[16], 치료 실패율이 높고[17], 출 생아의 장기간 관찰 시 비만 위험도가 증가하는 우려가 있 다[18].”
Thomas, A. M. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-112-3_10 · Cited by 6
Metformina: Uso clínico y actualización
Vicente, I. D., Betancourt, M. O., Rodríguez, L. A., Gallardo, S. B. R., Guifarro, M. A. R., & Ávila-Turcios, D. M. (2019) · Revista Médica Hondureña · doi:10.5377/rmh.v87i1.11935 · Cited by 6
Buote, N. J., Hayes, G. M., Bisignano, J., & Rosselli, D. (2021) · Journal of Feline Medicine and Surgery · doi:10.1177/1098612x211066477 · Cited by 6
Harreiter, J., & Kautzky‐Willer, A. (2016) · Wiener klinische Wochenschrift Education · doi:10.1007/s11812-016-0078-9 · Cited by 6
Yuen, L., Wong, V., Wolmarans, L., & Simmons, D. S. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18094588 · Cited by 8
“Furthermore, in LH there was an increase in the use of metformin, particularly after the favourable results from the MIG study [19], which likely cause a lowering of the short-acting insulin use in the IADPSG group.”
MethodResultBranch, D. W., & Heuser, C. C. (2010) · Springer eBooks · doi:10.1007/978-1-4419-1436-1_17 · Cited by 11
Metformin in pregnancy – safe or sorry?
Vanky, E., & Ødegård, R. A. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0081-6 · Cited by 6
Ryssdal, M., Skage, J. E., Jarmund, A. H., Hanem, L. G. E., Løvvik, T. S., Giskeødegård, G. F., Iversen, A., & Vanky, E. (2025) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.18320 · Cited by 5
“Three previous RCTs on pregnant women with gestational diabetes or type 2 diabetes found no difference in the incidence of maternal infections (reported as adverse events) [33–35].”
Zimmerman, D. A., Briffa, J. F., Kong, D., Gravina, S., Daygon, V. D., Kumar, V., Moritz, K. M., Lim, L. Y., Teo, A. K. K., Chan, S., et al. (2025) · The Journal of Physiology · doi:10.1113/jp289453 · Cited by 5
“Metformin and insulin treatment did not impact maternal weight gain, body composition, or fetal and placental weights, therefore initially supporting the clinical evidence of their overall safety during pregnancy (Rowan et al., 2008).”
Mobin, A., Obeid, A., El‐Kebbi, I. M., Everett, D., Ibrahim, S. M., Farhat, J., & Al‐Omari, B. (2024) · Chronic Diseases and Translational Medicine · doi:10.1002/cdt3.153 · Cited by 8
Dam, J. M. V., Goldsworthy, M. R., Hague, W. M., Coat, S., & Pitcher, J. B. (2021) · Brain Sciences · doi:10.3390/brainsci11030388 · Cited by 5
“8 years (mean ± SD), 10 female), all of whom participated in our previous study [5], were recruited from the Adelaide arm of the Metformin in Gestational diabetes (MiG) trial [16].”
BackgroundSelf-citationAnthony, N., Ahmad, A., Bibi, C., Amirzadah, W., Humayun, S., Sajid, M., Ashraf, Z., Abid, M., Khan, M. H., & Yousafzai, Z. A. (2021) · Cureus · doi:10.7759/cureus.17424 · Cited by 5
“A larger randomized controlled trial that compared metformin with insulin in the treatment of gestational diabetes (MiG trial) suggested that metformin, alone or with supplemental insulin, is an effective and safe treatment option in regards to glycemic control and feto-maternal outcomes [14].”
BackgroundZegarra, R. R., DALL’ASTA, A., Revelli, A., & Ghi, T. (2022) · Nutrients · doi:10.3390/nu14173562 · Cited by 5
“These recommendations are based on randomized clinical trials [104] and meta-analyses [105,106], which have shown similar outcomes when compared to patients with GDM treated with insulin.”
ResultKelly, L., Kattini, R., & Hummelen, R. (2023) · Canadian Journal of Rural Medicine · doi:10.4103/cjrm.cjrm_40_22 · Cited by 6
Treatment of Diabetes in Pregnancy With Metformin
Newman, C., & Dunne, F. (2024) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000005705 · Cited by 5
“27 This open-label trial randomized 700 individuals with confirmed GDM to metformin (with or without insulin) or insulin therapy, alone.”
Yu, Y., Platt, R. W., Reynier, P., Yu, O. H. Y., & Filion, K. B. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16115 · Cited by 6
Oral hypoglycemic agents: do the ends justify the means?
Langer, O. (2015) · Maternal Health Neonatology and Perinatology · doi:10.1186/s40748-015-0021-6 · Cited by 5
Kautzky-Willer, A., & Lemmens-Gruber, R. (2012) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-30726-3_15 · Cited by 4
“However, women with gestational diabetes randomly assigned to metformin or insulin therapy showed that metformin was as safe and efficient as insulin regarding maternal and foetal/neonatal outcome but women clearly preferred the oral anti-diabetic drug (Rowan et al. 2008).”
BackgroundGestational diabetes: screening for all, which test and which treatment?
Visser, G. H. A., & de Valk, H. W. (2012) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.12.7 · Cited by 5
Stirrat, L. I., Denison, F. C., Love, C. D., Lindsay, R. S., & Reynolds, R. M. (2015) · Scottish Medical Journal · doi:10.1177/0036933014563458 · Cited by 5
Predictors of Preeclampsia in Women in the Metformin in Gestational Diabetes(Mig) Study
Barrett, H. L. (2014) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000395 · Cited by 7
The Prevention of Gestational Diabetes
Giugliano, E., & Caserta, B. G. D. (2013) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000286 · Cited by 6
Current procedures for managing polycystic ovary syndrome
Massicotte, M.-H., Langlois, F., & Baillargeon, J. (2009) · Expert Review of Obstetrics & Gynecology · doi:10.1586/eog.09.74 · Cited by 5
Management of Gestational Diabetes Mellitus
Yu, S. H. (2017) · Hanyang Medical Reviews · doi:10.7599/hmr.2017.37.1.30 · Cited by 5
“3% of the metformin group required insulin treatment [22].”
BackgroundHajifaraji, M., & Dolatkhah, N. (2017) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 11
Metformin in women with type 2 diabetes in pregnancy
Bailey, C. J. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30308-9 · Cited by 5
McLean, A., Katz, M., Oats, J. J. N., Wang, Z., Barr, E., & Maple-Brown, L. J. (2021) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/ajo.13281 · Cited by 5
Versace, V. L., Beks, H., Hannah, W., Namara, K. M., Hague, W. M., Anjana, R. M., Mohan, V., Khunti, K., & Dunbar, J. (2020) · Seminars in Reproductive Medicine · doi:10.1055/s-0041-1727203 · Cited by 5
Self-citationQuadir, H. (2021) · Cureus · doi:10.7759/cureus.18818 · Cited by 6
“Birthweight and rate of large for gestational age (LGA) were similar in both groups with a lesser rate of hypoglycemia in the metformin group [10].”
BackgroundXargay‐Torrent, S., Mas‐Parés, B., Carreras‐Badosa, G., Lizárraga-Mollinedo, E., Tibau, J., Reixach, J., Platero-Gutierrez, E., Prats‐Puig, A., de Zegher, F., Ibáñez, L., et al. (2022) · International Journal of Obesity · doi:10.1038/s41366-022-01076-5 · Cited by 5
“Few studies have been published in human cohorts examining the relationship of GWG with offspring’s DNA methylation using whole methylome International Journal of Obesity approaches in placenta [44] and umbilical cord blood [45, 46].”
InfluentialAntenatal insulin therapy in gestational diabetes mellitus: validation of the new Brugmann scores
Badr, D. A., Kassem, C., Carlin, A., Dobrescu, O., Iconaru, L., Baleanu, F., Taujan, G. C., & Jani, J. C. (2022) · Gynecological Endocrinology · doi:10.1080/09513590.2022.2048296 · Cited by 5
“The MiG Trial was one of the first randomized controlled trials to demonstrate the advantages of metformin, an oral biguanide, in the treatment of resistance cases of gestational diabetes [15].”
Backgroundvan Hoorn, E. G. M., Rademaker, D., van der Wel, A. W. T., DeVries, J. H., Franx, A., van Rijn, B. B., Kooy, A., Siegelaar, S. E., Roseboom, T. J., Ozanne, S. E., et al. (2023) · Diabetic Medicine · doi:10.1111/dme.15243 · Cited by 6
“1,7,61,64 In addition, insulin has several disadvantages.”
He, Y., Huang, Z., Wei, C., & Chen, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1220957 · Cited by 5
“Thus, patients may prefer metformin to insulin in clinical practice (50).”
BackgroundSivadasan, S., Subramanian, M., & Aiyalu, R. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.99815 · Cited by 5
“The study of metformin in pregnancy revealed that the use of metformin in women with GDM was not associated with increased risk of congenital anomalies, or maternal and neonatal complications compared to insulin, except for higher rates of preterm labour [44].”
BackgroundDiabetes Mellitus Complicating Pregnancy
Landon, M. B., Catalano, P. M., & Gabbe, S. G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-32108-2.00040-8 · Cited by 7
Metformin: an important tool for endocrinology in the West Indies. New tricks for an old drug
Teelucksingh, S., & Pereira, L. M. P. (2009) · The British Journal of Diabetes · doi:10.1177/1474651409346766 · Cited by 5
Traitement du diabète gestationnel par hypoglycémiants oraux
Carles, G., Germain, L., Alassas, N., Guindi, W. E., Dallah, F., & Daigre, J.-L. (2010) · Journal de gynécologie, obstétrique et biologie de la reproduction. Supplément/Journal de gynécologie obstétrique et biologie de la reproduction · doi:10.1016/j.jgyn.2009.12.002 · Cited by 9
Metformin: Midlife maturity, maiden charm
Kalra, S., Dhamija, P., & Das, A. (2012) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.103028 · Cited by 6
“Apart from its glycemic effects in type 2 diabetes, for which it is approved, it is used in other forms of diabetes such as pre-diabetes,[1] type 1 diabetes[2] and gestational diabetes mellitus.[3] Its properties have also been put to use in other facets of metabolic syndrome, such as obesity,[4] non-alcoholic fatty l…”
Background
Metadata
- Authors
- Rowan, J. A., Hague, W. M., Gao, W., Battin, M. R., & Moore, M. P.
- Affiliations
- Auckland City Hospital (NZ)
- Women's and Children's Hospital (AU)
- Auckland University of Technology (NZ)
- University of Auckland (NZ)
- Christchurch Hospital (NZ)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-05-08
- Volume
- 358
- Issue
- 19
- Pages
- 2003-2015
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2003621575
- Cited by
- 1,291
- References
- 33
- Citations by year
- 2026: 49 · 2025: 60 · 2024: 52 · 2023: 65 · 2022: 63 · 2021: 90 · 2020: 67 · 2019: 66 · 2018: 105 · 2017: 125 · 2016: 68 · 2015: 82 · 2014: 69 · 2013: 62 · 2012: 56
- FWCI
- 78.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- metformin, insulin, gestational diabetes mellitus, neonatal hypoglycemia, perinatal complications, maternal glycemic control, postpartum glucose tolerance, treatment acceptability, treatment preferences, neonatal respiratory distress, phototherapy
- MeSH terms
- Adult, Drug Therapy, Combination, Female, Gestational Age, Humans, Hypoglycemia, Hypoglycemic Agents, Infant, Newborn, Insulin, Jaundice, Neonatal, Metformin, Pregnancy, Pregnancy Complications, Cardiovascular, Pregnancy Outcome, Diabetes, Gestational, Patient Satisfaction, Premature Birth
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.